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Background
In the last decade anti-HER2 treatment became one of
the best examples for targeted treatment. Since the
aggressive behavior of HER2-positive breast cancers
could have been successfully reduced by trastuzumab
therapy, HER2 positive breast cancers recently show
improving prognosis. According to a four-tiered classifi-
cation of international clinical guidelines, cases with
strong and complete staining (IHC 3+) with anti-HER2
antibodies are eligible for trastuzumab therapy. The
cases with complete, but moderate anti-HER2 stainings
(2+ or equivocal) should be further investigated with (F)
ISH-technique to determine HER2-amplification [1].
Negative and IHC 3+ cases are easy to interpret semi-
quantitatively on routine immunohistology, it is hard to
conclude on the equivocal cases, sill, anti-HER2 therapy
is indicated upon the predictive pathology report of
HER2-expression and interobserver variability of IHC-
interpretation still remains rather high [2]. Furthermore,
the response rate of patients to the rather expensive tra-
tuzumab therapy that might be accompanied by side
effects is still only about 50% [3]. The rapidly developing
digital pathology solutions have promised better ways of
archiving, documenting and standardizing immunohisto-
chemistry including image analysis of HER2 detection to
improve the efficacy of targeted anti-HER2 therapy [4].
MembraneQuant application of Pannoramic Viewer
platform (3DHISTECH, Budapest, Hungary) offers stan-
dardized way for semi-automated scoring of membrane-
staining. Our aim was to validate MembraneQuant
application against semi-quantitative routine scoring of
HER2 IHC slides in order to improve prediction of
HER2 gene amplification status.
Materials and methods
Patients
We selected invasive breast cancers from year 2002-to
2005 from the archive of the 1st Department of Pathol-
ogy and Experimental Cancer Research of the Semmel-
weis University, Budapest, Hungary. 100 invasive ductal
carcinomas were used in TMAs (created with TMA
Master, 3DHISTECH Ltd, Budapest, Hungary) of 2mm
cores of formalin-fixed paraffin embedded breast cancer
specimens from females aged 26-86 years. The survey
was performed with the permission of the Ethical Com-
mittee. TMA slides were used for HER2 IHC according
to manufacturer’s protocol on a Bond-maxTM fully auto-
mated staining system (Leica Microsystems GmbH, Ger-
many), using PATHWAY® HER-2/neu (clone 4B5,
Ventana, USA), whereas their duplicates were used for
HER2-FISH testing by the Rembrandt Her2/Neu - Cen
17 FISH kit (PP-C801K.5206, Biomedica kft. Budapest).
Digitalization platform
Digitalization was performed using a Pannoramic SCAN
digital slide scanner (3DHISTECH) using Zeiss plan-
apochromat objective (magnification: 20X, Numerical
aperture: 0.8) and Hitachi (HV-F22CL) 3CCD progres-
sive scan color camera (resolution: 0.2325 µm/pixel).
For fluorescent slides Zeiss (AxioCam MRm Rev. 3)
monochrome microscopy camera (resolution: 0.322500
µm/pixel) was used which has high spectral sensitivity.
Digital evaluation of slides
In our application a color deconvolution algorithm was
applied to separate the signal of immunoreactive cell
membranes in the brown channel (DAB signal) from the
counterstain blue channel (hematoxilin signal). The
color deconvolution algorithm generates two different
grayscale images which are separately processed. The
membrane detection algorithm runs on the brown,
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whereas the cell nuclei detection on the blue channel.
The immune-negative epithelial cells have no membrane
stain so these cells are to be detected on their cell nuclei
on hematoxilin signal. The processing of the cell nuclei
segmentation is similar to the NuclearQuant application
which has been previously described [5].
Cell membrane immunostained slides can be
described as connected pixel curve of local minima of
intensity in DAB image. The intensity based linking
algorithm was developed to segment the image into
adjacent spots whose border potentially marks the mid-
dle of the membranes lines (skeleton). Some false curves
can appear at local minima where is no actual immun-
reaction presented, therefore adjacent spots which have
suboptimal features should be merged. Merging criteria
are based on area of the spots and the length of neigh-
boring border segments. Further false curves can be
eliminated based on nuclei segmentation: adjacent spots
are merged which has common border segment over a
nuclei. After successful subtraction of membrane and
nuclei segmented mask images spots are disclosed
which could not represent membranes based on their
size. Average intensity of DAB image is measured along
the border of spot locations to be used for classification
(scoring) [6].
MembraneQuant detects all cells and counts individu-
ally its specific staining in a region of interest (Figure 1).
These proportional and intensity data later combined to
a Field Score according to the guidelines, but all other
data can be extracted from the digital analysis (e.g. H-
Score, Label area, mask area, number of detected objects).
Semiquantitative-scoring of the slides
Visual scoring of the digitized HER2 slides was per-
formed blinded with regards of the original HER2
scores. A pathologist reviewed the digital TMA-cores
using Pannoramic Viewer application (3DHISTECH)
and provided a HER2 score and selected 1 to 4 annota-
tions of tumorous tissue as regions of interest (ROI) on
each core and scored them individually. Altogether 226
annotations were selected and analyzed using Membra-
neQuant and the scores of the ROI on one core were
summarized into an overall core score, which was used
for the data analysis.
FISH scoring and settings of MembraneQuant were
equivalent to the international HER2- ASCO/CAP scor-
ing guidelines [1]. Data analysis of the immunreaction
was performed using the Statistica 9.1 (StatSoft Inc,
Tulsa USA).
Agreement between the different scorings was calcu-
lated using Cohen’s kappa. The strength of agreement
was interpreted as proposed by Landis & Koch [7]. In
order to test the clinical relevancy of the agreement,
quadratic weighted kappa was calculated as well, by
assigning the following weights: 1 for total agreement;
0.89 for 0 vs. 1+ or 2+ vs. 3+ or 1+ vs. 2+; 0.56 for 0 vs.
2+; 0 for 0 vs. 3+. the weight 0 for the most relevant
disagreement (i.e. 0 for 2+ vs. 3+). The strength of the
agreement was additionally assessed using the Spearman
rank-correlation coefficient.
Results and discussion
Cohen’s kappa revealed an almost perfect agreement
( = 0.857, 95%CI = 0.750-0.929) between the scores
provided by the pathologists and those by Membrane-
Quant. While testing the agreement for clinical rele-
vancy, this proved to be an almost perfect correlation,
as showed by the high quadratic weighted kappa value
( = 0.962, 95%CI = 0.939-0.986). Spearman rank-corre-
lation also provided a highly significant correlation
between the results (Spearman’s rho = 0.933, df = 99,
p < 0.0001, 95% CI for rho 0.903-0.955).
Figure 1 Digital analysis of scanned slides The DAB-imunostaining levels are detected on the brown-channel. MembraneQuant detects the
nuclei on the blue channel to identify the cells of the ROI, than calculates an intensity topographic map to classify each cell to a distinct class,
which is later on calculated to a field score (here the strong, complete membrane staining was of a 3+ score). On the result-slide the positivity-class
of the cells are color-coded (blue: nucleus, yellow: 1+, orange: 2+, red: 3+).
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In the 15 equivocal cases 9 were found FISH-, while 6
were FISH+. During digital processing of IHC-slides
MembraenQuant calculates different values for each cell,
which data were later analyzed in all the FISH tested
cases in order to predict HER2 amplification status.
There was a trend towards lower HER2-negative cell
number and higher 2+ cell number in FISH-ve cases,
while FISH+ve cases had significantly higher 3+ cell
number. By multiplying the frequency of positive cells
with the class of IHC-positivity given by the software we
calculated the H-Score for all ROIs and found a border-
line significant difference between the FISH+ve and
FISH-ve cases with elevated H-score in the FISH+ cases.
Among the data counted by the MembraneQuant we
also found other significant differences and one of the
most promising was within the ’mask area of objects in
different classes’ (LO-CMA) to differentiate between
FISH+ve and FISH-ve cases (Table 1 and Figure 2).
Table 1 Differences in membrane-stainings according to FISH-positivity.
FISH - FISH + FISH - FISH + FISH - FISH + FISH - FISH + FISH - FISH + FISH - FISH +





















Average 0.08386 0.152766 0.012607 0.04071 61.25344 88.80895 7315.882 25794.81 1317.471 12464.48 184.7127 2866.724
SD 0.107272 0.135455 0.024028 0.047413 42.95535 48.74765 4898.122 21455.78 1796.785 15429.72 365.2118 4210.592
Min. 0 0 0 0 3.007519 9.550562 207.6841 1472.817 0 0 0 0
Max. 0.28777 0.408517 0.098592 0.162461 136.6906 170.5047 19422.9 67658.91 5221.888 46501.73 1549.739 11813.45
MembraneQuant calculates intensity scores for each cell within an annotation and additional proportional score. Significant difference is highlighted underlining;
italics indicates strong tendency. FISH+ cases had significantly higher HER2-IHC3+ proportional score, while IHER2-IHC2+ proportional score and H-score had a
tendency of higher occurrence in the FISH+ cases. In our set, the most significant differences (underlined) were found between FISH-positive and negative cases
in the label-area of different IHC-intensity classes.
Figure 2 Graphs of significant findings according to FISH-positivity. Legend: According to data in Table 1. significant findings were
visualized with variability plots and p-values are indicated in each graph. Most significant differences were found in the Label Area and within
the HER2 3+ proportional score, while strong tendency was found in H-Score according to FISH-positivity. Only trend was found in HER2 2+
proportional score.
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The anti-HER2 targeted therapy is indicated upon
strong (3+) HER2-IHC staining which correlates well with
the HER gene amplification measured by FISH [6]. FISH,
however, requires special infrastucture accessed by only
limited number of laboratories and several studies have
concluded, that protein expression level might correlate
better with the efficacy of trastuzumab therapy [3]. The
four-tiered classification of HER2 immunohistochemsitry
may not be a sufficient thumbrule and there is an increas-
ing amount of information suggesting that a continous
HER2-score might correlate better to the response to tras-
tuzumab therapy [8]. In our approach, the different data-
sets generated during the processing of digital slides might
help to better differentiate markers of HER2-amplification,
which may not be evaluated consistently by the patholo-
gist’s eyes during the semi-quantitative analysis. Membra-
neQuant application calculates the proportional score for
each intensity class (0 to 3+) and also many other further
derivatives on the annotated ROI areas related to our digi-
tal immunohistochemistry data, which may be used to
validate HER2-IHC and its predictive value on HER2-
amplification.
We found lower 0 proportional score, and higher 2+,
3+ proportional score and H-score in FISH-positive
cases on a set of 15 equivocal cases further assesed with
FISH. 3+ proportional score was significantly higher in
FISH+ cases, and we also found more datasets (without
known clinical meaning) derived by the algorythm,
which showed highly significant differences in correla-
tion with the FISH-findings. Althought, the negative and
positive predictive values for reliable detection of FISH-
amplification should be calculated on a higher sample
number, our findings are promising since there are sev-
eral other HER2 digital analysis platforms [8-10]. How-
ever, these platforms are based on more difficult and
complex investigations and use more antibodies and
fluorescent dyes. Our analysis relies on a standard qual-
ity IHC-reaction gained with a highly specific antibody
(clone 4B5) and uses multiple factors to predict HER2-
amplification.
Conclusion
We validated MembraneQuant application of Pannora-
mic Viewer platform by finding an almost perfect corre-
lation between digital and semi-quantitative evaluation
of HER2-IHC slides (quadratic  = 0.962, Spearman’s
rho = 0.933). Furthermore, we found several significant
differences in the staining-patterns of the equivocal
cases, which could help to discriminate between FISH-
positive and negative cases by combining the 4-tiered
classification with other digitally-derived sample data.
We strongly believe, that digital image analysis methods
- digital immunohistochemistry - can improve the effi-
cacy of anti-HER2 therapy by standardizing the
evaluation protocols and finding discriminative patterns
within digital data sets to detect HER2-amplification.
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